Patrys’ Contract Development Manufacturing Organisation (CDMO) advised the Company that it has identified an inconsistency with one of the processes used in specification testing which is currently being rectified. In view of this, the CDMO has advised that specification testing for the drug substance produced in the recent manufacturing run of PAT-DX1 is now expected to be complete in the second half of August 2024. This specification testing must be successfully completed for the drug material to be released for use in clinical trials.